In Silico Exploration of AHR-HIF Pathway Interplay: Implications for Therapeutic Targeting in ccRCC
Genes · 2024
DOI: 10.3390/genes15091167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2024. Verfasst von Francesco Gregoris und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, University of Padova, Viale G. Colombo 3, 35121 Padova, Italy. Hauptthemen laut MEDLINE: Receptors, Aryl Hydrocarbon, Carcinoma, Renal Cell, Von Hippel-Lindau Tumor Suppressor Protein, Basic Helix-Loop-Helix Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research, Fondazione AIRC per la Ricerca sul Cancro (AIRC).
Abstract (Originalsprache)
The oxygen-sensing pathway is a crucial regulatory circuit that defines cellular conditions and is extensively exploited in cancer development. Pathogenic mutations in the von Hippel–Lindau (VHL) tumour suppressor impair its role as a master regulator of hypoxia-inducible factors (HIFs), leading to constitutive HIF activation and uncontrolled angiogenesis, increasing the risk of developing clear cell renal cell carcinoma (ccRCC). HIF hyperactivation can sequester HIF-1β, preventing the aryl hydrocarbon receptor (AHR) from correctly activating gene expression in response to endogenous and exogenous ligands such as TCDD (dioxins). In this study, we used protein–protein interaction networks and gene expression profiling to characterize the impact of VHL loss on AHR activity. Our findings reveal specific expression patterns of AHR interactors following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and in ccRCC. We identified several AHR interactors significantly associated with poor survival rates in ccRCC patients. Notably, the upregulation of the androgen receptor (AR) and retinoblastoma-associated protein (RB1) by TCDD, coupled with their respective downregulation in ccRCC and association with poor survival rates, suggests novel therapeutic targets. The strategic activation of the AHR via selective AHR modulators (SAhRMs) could stimulate its anticancer activity, specifically targeting RB1 and AR to reduce cell cycle progression and metastasis formation in ccRCC. Our study provides comprehensive insights into the complex interplay between the AHR and HIF pathways in ccRCC pathogenesis, offering novel strategies for targeted therapeutic interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, University of Padova, Viale G. Colombo 3, 35121 Padova, Italy.
ORCID-Profile: Giovanni Minervini, Silvio C E Tosatto
Förderung
- Italian Association for Cancer Research
- Fondazione AIRC per la Ricerca sul Cancro (AIRC)
Zitieren
APA
Gregoris, F., Minervini, G., & Tosatto, S. C. E. (2024). In Silico Exploration of AHR-HIF Pathway Interplay: Implications for Therapeutic Targeting in ccRCC. Genes. https://doi.org/10.3390/genes15091167
Vancouver
Gregoris F, Minervini G, Tosatto SCE. In Silico Exploration of AHR-HIF Pathway Interplay: Implications for Therapeutic Targeting in ccRCC. Genes. 2024. doi:10.3390/genes15091167
BibTeX
@article{Gregoris2024,
author = {Gregoris, Francesco and Minervini, Giovanni and Tosatto, Silvio C E},
title = {In Silico Exploration of AHR-HIF Pathway Interplay: Implications for Therapeutic Targeting in ccRCC},
journal = {Genes},
year = {2024},
doi = {10.3390/genes15091167}
}
EUVIMED